House vote on Pelosi drug pricing plan slips to December

House vote on Pelosi drug pricing plan slips to December
© Greg Nash

The House will not vote on Speaker Nancy PelosiNancy PelosiNJ governor calls for assessment of coronavirus response after crisis abates Overnight Health Care: Global coronavirus cases top 1M | Cities across country in danger of becoming new hotspots | Trump to recommend certain Americans wear masks | Record 6.6M file jobless claims Hillicon Valley: Zoom draws new scrutiny amid virus fallout | Dems step up push for mail-in voting | Google to lift ban on political ads referencing coronavirus MORE’s (D-Calif.) signature plan to lower drug prices until December as the timeline for taking up the bill slips again. 

A senior Democratic aide said Wednesday that the Congressional Budget Office needs another two weeks to complete its analysis of the legislation, meaning there will not be time for the House to vote on the bill before lawmakers leave for the Thanksgiving recess. 

ADVERTISEMENT

Pelosi unveiled the plan in September and had initially hoped to vote on it by late October or early November. 

But the CBO analysis is taking longer than expected. 

Politico first reported the delay in the bill’s timeline on Wednesday. 

A preliminary analysis found that the main section of the bill would save $345 billion over seven years. 

The measure would allow the secretary of Health and Human Services to negotiate lower prices on up to 250 drugs per year, with savings applied to people on private insurance in addition to those on Medicare. 

The measure is expected to pass the House on a largely party line vote and will likely die in the Senate, where Senate Majority Leader Mitch McConnellAddison (Mitch) Mitchell McConnellDemocrats press Trump, GOP for funding for mail-in ballots Top GOP lawmakers push back on need for special oversight committee for coronavirus aid Stocks move little after record-breaking unemployment claims MORE (R-Ky.) has called it “socialist.”

It is possible some smaller drug pricing measures could be included in a government funding deal at the end of the year, but that remains uncertain. 

Pelosi’s office has been in talks with the White House for months on the legislation, given President TrumpDonald John TrumpMilitary personnel to handle coronavirus patients at facilities in NYC, New Orleans and Dallas Navy hospital ship USNS Comfort has total of 20 patients: report Fauci says that all states should have stay-at-home orders MORE’s sharp rhetoric on drug prices, but the White House has recently been backing away from the bill in favor of a more modest bipartisan measure in the Senate. 

There are also some bumps to be overcome in the House. Progressives are still pushing for changes to make the bill stronger, despite the fears of some moderate Democrats about pushing the measure farther to the left.